
High-performance liquid chromatography (HPLC) confirms safe blood levels of slow-release bupivacaine nanoparticles.
SEC data demonstrates mRNA aggregate analysis for vaccine stability. Optimal separation occurs at 100 mM NaCl and low flow rates, enhancing mRNA production quality.





